Allt inom Yearend

The year ended strongly with an important milestone; the license and option agreement with Moderna, which is an important validation of our technology and has created favourable conditions for 2026 and beyond

The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025.